OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million
Mar 12, 2025, 12:17 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strong earnings beat consensus, indicating positive market reception and potential for continued growth. Historically, strong quarterly earnings often correlate with price appreciation, as seen in past earnings surprises by growth companies.
AI summary
What happened, with direct paths to the underlying reporting
OPRX reported Q4 sales of $32.32 million, up 14% year-over-year. Adjusted EPS was 30 cents, exceeding analyst expectations. Full-year revenue reached $92.1 million, a 29% growth from last year. CEO highlights strategic positioning for future growth in digital healthcare. 2025 revenue projected at $100 million, surpassing consensus estimates.
OPRX reported Q4 sales of $32.32 million, up 14% year-over-year.
Adjusted EPS was 30 cents, exceeding analyst expectations.
Full-year revenue reached $92.1 million, a 29% growth from last year.
CEO highlights strategic positioning for future growth in digital healthcare.
2025 revenue projected at $100 million, surpassing consensus estimates.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
OptimizeRx Corp is experiencing a drop in share price due to heightened market volatility and concerns regarding Most Favored Nation pricing. This uncertainty could pose risks to…